Cholesterol; Metabolic Disorder, Inflammation
Conditions
Keywords
Atherosclerosis, cardiovascular disease, high-sensitivity C-reactive protein, inflammation, sheep ghee
Brief summary
Normal volunteers were randomly received Sheep ghee or sunflower oil, and before and after the study lipid profile and HS-CRP were measured.
Detailed description
During outpatient clinic visits, potentially eligible individuals were screened for enrollment according to the inclusion and exclusion criteria. Patients were randomly allocated into the treatment and control groups via the blocked randomization method. The control group received a normal diet for eight weeks with 10 g of sunflower oil. In the treatment group, sunflower oil was replaced with 10 g of sheep ghee. 50 patients in each group were enrollment. Patients' information, including demographic data and the serum levels of fasting blood sugar (FBS), LDL, HDL, triglyceride (TG), and hs-CRP, were recorded in datasheets twice: once before treatment with sheep ghee and once eight weeks later.
Interventions
DIETARY_SUPPLEMENTsheep ghee
natural sheep ghee, given to patient in a commercial box and intervention group 10 gr per day from sheep ghee
DIETARY_SUPPLEMENTsunflower oil
natural sunflower oil, given to patients in a commercial box and patient use 10 gr of it
Sponsors
Shiraz University of Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
random allocation, open label
Intervention model description
clinical trial randomized
Eligibility
Sex/Gender
ALL
Age
20 Years to 76 Years
Healthy volunteers
Yes
Inclusion criteria
* healthy adults, seeking outpatient visit at professor kojuri cardiology clinic
Exclusion criteria
* any history of ischemic heart disease (IHD), * coronary artery bypass grafting (CABG) * percutaneous intervention (PCI) * stroke * peripheral vascular diseases * use of anti-hyperlipidemic agents * unwillingness to participate. * Need of tight hyperlipidemia control.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| LDL cholesterol | 2 months | serum LDL level in mg/dl |
| total cholesterol | 2 months | serum total cholesterol in mg/dl |
| HDL cholesterol | 2 months | Serum HDL in mg/dl |
| HS-CRP | 2 months | HS-CRP level in picogram/dl |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| adverse effect | 2 months | gastrointestinal, skin, allergy |
Countries
Iran
Outcome results
None listed